The goals of the core are to provide all projects with centralized leadership and administrative support, and to ensure effective communication among all projects and cores so that objectives are being met, To achieve this goal the core will arrange internal group meetings, including the monthly investigator meeting, executive committee meetings and invited research lectures, It will oversee the overall fiscal and budgetary management of the PPG and provide assistance to each project and core leader, with a particular focus on assisting budgetary planning. Over the last 9 years of funding, this core has monitored each project with input from the Executive Committee and Scientific Advisory Board, and modified projects and incorporated new directions as necessary. For the current proposal, the Administrative Core leaders will ensure continued PPG oversight by convening meetings of the Scientific Advisory Board, which consists of both internal and external investigators with expertise In the field, and assessing and implementing their recommendations. This core also supervises;the Good Laboratory Practice (GLP) Laboratory which accessions follow up samples from patients on clinical trials and enters details into a database to allow subsequent follow up testing;and a CLIA certified flow cytometry laboratory that analyzes samples from our human subjects research . Finally the Administrative Core will communicate with the NCI program staff and encourage and facilitate collaboration with other NCI translational initiatives.

Public Health Relevance

; The Administrative Core supports the leadership of all projects and cores. It organizes meetings to monitor progress and promote collaboration and obtains external advice on program performance from a Scientific Advisory Board.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA094237-12
Application #
8933454
Study Section
Special Emphasis Panel (ZCA1-RPRB-B (O1))
Program Officer
Merritt, William D
Project Start
2014-02-01
Project End
2018-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
12
Fiscal Year
2014
Total Cost
$95,120
Indirect Cost
$34,244
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Heslop, Helen E; Brenner, Malcolm K (2018) Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther 26:1-2
Mamonkin, Maksim; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2018) Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res 6:47-58
Kalra, Mamta; Gerdemann, Ulrike; Luu, Jessica D et al. (2018) Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy :
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139
Lyon, Deborah; Lapteva, Natasha; Gee, Adrian P (2018) Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples. Mol Ther 26:6-7
Shum, Thomas; Kruse, Robert L; Rooney, Cliona M (2018) Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opin Biol Ther 18:653-664
Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34
McLaughlin, Lauren P; Rouce, Rayne; Gottschalk, Stephen et al. (2018) EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood 132:2351-2361
Mata, Melinda; Gerken, Claudia; Nguyen, Phuong et al. (2017) Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models. Cancer Discov 7:1306-1319
Tzannou, Ifigeneia; Papadopoulou, Anastasia; Naik, Swati et al. (2017) Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol 35:3547-3557

Showing the most recent 10 out of 217 publications